Skip to main content

Teva Pharmaceutical Industries ADR(TEVA-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low30.02
Day High31.45
Open:31.26
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Piper Sandler Remains a Buy on Teva Pharmaceutical (TEVA)
Motley Fool
3 Catalysts That Could Send Teva Stock to $40 and Beyond
Zacks Investment Research
J&J Targets Double-Digit Growth by 2030 Despite Stelara Drag
J&J Targets Double-Digit Growth by 2030 Despite Stelara Drag
GlobeNewswire
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
GlobeNewswire
Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics
Tipranks
Analysts Are Bullish on These Healthcare Stocks: InflaRx (IFRX), Teva Pharmaceutical (TEVA)
Zacks Investment Research
Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?
Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?
Tipranks
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Nuvation Bio (NUVB) and Argenx Se (ARGX)
Zacks Investment Research
TEVA's Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted
TEVA's Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted
Tipranks
Barclays Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)
GlobeNewswire
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
Tipranks
UBS Remains a Buy on Teva Pharmaceutical (TEVA)
Tipranks
Scotiabank Remains a Buy on Teva Pharmaceutical (TEVA)
Motley Fool
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition
GlobeNewswire
Teva Releases Q1 2026 Aide Memoire
GlobeNewswire
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
Motley Fool
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
Motley Fool
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
Motley Fool
The 3 Best Stocks to Invest $1,000 in Right Now
Tipranks
J.P. Morgan Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Teva Pharmaceutical (TEVA), Aquestive Therapeutics (AQST)
Zacks Investment Research
Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's
Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's
Motley Fool
Forget Teva: This Dividend Top Dog Is the Real Value Buy Today
Zacks Investment Research
3 Generic Drug Stocks to Watch Despite Industry Headwinds
3 Generic Drug Stocks to Watch Despite Industry Headwinds
Motley Fool
Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding
GlobeNewswire
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
Motley Fool
The Best Healthcare Stock to Invest $1,000 in Right Now
Motley Fool
Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole
Zacks Investment Research
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?
Motley Fool
Bridger Dumps 301,000 Bath & Body Works Shares Worth $7.7 Million
GlobeNewswire
Teva to Present at the Upcoming Investor Conferences in March
Motley Fool
Inside a $75 Million Albertsons Stock Sale as Shares Sink 8% in a Year

Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.